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Background: Pulmonary arterial hypertension (PAH) is a vascular remodeling disease characterized by enhanced
proliferation of pulmonary artery smooth muscle cell (PASMC) and suppressed apoptosis. This phenotype has been
associated with the upregulation of the oncoprotein survivin promoting mitochondrial membrane potential
hyperpolarization (decreasing apoptosis) and the upregulation of growth factor and cytokines like PDGF, IL-6 and
vasoactive agent like endothelin-1 (ET-1) promoting PASMC proliferation. Krüppel-like factor 5 (KLF5), is a zinc-
finger-type transcription factor implicated in the regulation of cell differentiation, proliferation, migration and
apoptosis. Recent studies have demonstrated the implication of KLF5 in tissue remodeling in cardiovascular
diseases, such as atherosclerosis, restenosis, and cardiac hypertrophy. Nonetheless, the implication of KLF5 in
pulmonary arterial hypertension (PAH) remains unknown. We hypothesized that KLF5 up-regulation in PAH triggers
PASMC proliferation and resistance to apoptosis.
Methods and results: We showed that KFL5 is upregulated in both human lung biopsies and cultured human
PASMC isolated from distal pulmonary arteries from PAH patients compared to controls. Using stimulation
experiments, we demonstrated that PDGF, ET-1 and IL-6 trigger KLF-5 activation in control PASMC to a level similar
to the one seen in PAH-PASMC. Inhibition of the STAT3 pathway abrogates KLF5 activation in PAH-PASMC. Once
activated, KLF5 promotes cyclin B1 upregulation and promotes PASMC proliferation and triggers survivin expression
hyperpolarizing mitochondria membrane potential decreasing PASMC ability to undergo apoptosis.
Conclusion: We demonstrated for the first time that KLF5 is activated in human PAH and implicated in the pro-
proliferative and anti-apoptotic phenotype that characterize PAH-PASMC. We believe that our findings will open
new avenues of investigation on the role of KLF5 in PAH and might lead to the identification of new therapeutic
targets.
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Background
Pulmonary arterial hypertension (PAH) is a vascular dis-
ease that is mainly restricted to small pulmonary
arteries. PAH occurs in rare idiopathic and familial
forms, but is more commonly part of syndromes
associated with connective tissue diseases, anorexigen
use, HIV or congenital heart disease. This syndrome of
obstructed, constricted small pulmonary arteries (PA)
has been attributed to abnormalities in the blood con-
tent of some neurotransmitters and cytokines, namely
increases in serotonin, IL-6, PDGF and endothelin-1
[1-4]. We recently demonstrated that the increase in
these circulating vasoactive agents triggers in pulmonary
artery smooth muscle cells (PASMC) the activation of
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ing to increase [Ca
2+]i-mediated PASMC proliferation
[5,6]. Moreover, we showed a sustained increase in the
oncoprotein survivin, decreasing mitochondrial-depen-
dent apoptosis [7]. The fact that the PAH phenotype is
preserved in cultured PASMC isolated from PAH
patients suggests that the PAH phenotype is sustained
independently of the circulating growth factors or ago-
nists but requires genetic remodeling processes [8,9].
Moreover, despite recent therapeutic advances such as
endothelin-1 receptor blockers (e.g. bosentan) [10], type
5 phosphodiesterase inhibitors (e.g. sildenafil) [11] or
PDGF receptor blockers (e.g. imanitib) [12], mortality
rates remain high [13].
Krüppel-like factor 5 is a zinc finger transcription fac-
tor that belongs to a family known as the Sp/KLF fac-
tors, and is implicated in important biological functions
including cell proliferation, apoptosis, development, and
oncogenic processes [14-16]. In Vascular Smooth Mus-
cle Cells (VSMC) KLF5 regulates expression of the
embryonic form of smooth muscle myosin heavy chain
(SMemb/NMHC-B), which is selectively expressed in
the proliferative dedifferentiated smooth muscle pheno-
type. In systemic vessels, KLF5 is expressed in proliferat-
ing smooth muscle cells of coronary artery lesions [17],
and expression of this factor in lesions is clinically asso-
ciated with restenosis and cardiac allograft vasculopathy
[17]. KLF5 expression is therefore associated with prolif-
erating smooth muscle cells in the cardiovasculature
[18,19]. However, it had yet to be shown whether KLF5
is activated in PAH-PASMC and whether it’s implicated
in PASMC proliferation and apoptosis.
Materials and methods
All experiments were performed in accordance to the
Université Laval’s Ethic and Biosafety Committee (proto-
col number 20142) and the Centre Hospitalier Universi-
taire de Québec’s Ethic’s Committee.
Human tissue samples
All patients gave written informed consent before the study.
Healthy lung tissues (controls) were obtained during lung
resection for tumors. Only the healthy parts of the lungs
were used in this study. All the PAH tissues were from lung
explants from transplant or autopsy (Table 1).
Cell culture
Cells were used in the first to sixth passage. Pulmonary
arterial endothelial cell (PAEC), isolated form healthy
human pulmonary arteries, were bought form the Cell
application inc. (#302K-05a). PAH-PASMC were obtained
from ≈1, 5 μm-diameter small pulmonary arteries from 2
males with iPAH (31 and 48 years old) and 1 female with
PAH group 1 (54 years old) from lung explants. Age and
sex matched control PASMC (3 males 45; 21; 64 years old
and 2 females 17 and 35 years old)) were used. All patients
had right catheterization that confirmed pulmonary hyper-
tension (mean PAP greater than 25 mmHg at rest).
PASMC were grown in high-glucose DMEM supplemen-
ted with 10% Fetal Bovine Serum (Gibco, Invitrogen,
Table 1 Patients providing tissue
Patient type Sex Age Mean PA pressure (mmHg) Medications PVR (dyne*sec)/cm
5 Lung tissue
1 Control (Benign tumor) F 35 ND None ND Yes
2 Control (Lung Cancer) F 38 ND None ND Yes
3 Control (Benign tumor) M 45 ND None ND Yes
4 Control (Lung Cancer) M 51 ND None ND Yes
5 Control (Hodgkin) M 48 ND None ND Yes
6 Control (Benign tumor) F 44 ND None ND Yes
7 Control (Lung Cancer) F 47 ND None ND Yes
8 Control (Lung Cancer) F 50 ND None ND Yes
9 iPAH F 58 56 Epoprostenol/Lasix/Coumadin 1709 Yes
10 iPAH F 36 67 Epoprostenol/Lasix/Coumadin 2274 Yes
11 SSC-PAH F 55 48 Epoprostenol/Lasix/Coumadin 980 Yes
12 PAH group1 F 64 59 Bosentan/Lasix 926 Yes
13 PAH group1 M 72 39 Lasix/Sitaxsentan 550 Yes
14 PAH group1 M 58 42 Epoprostenol/Lasix/Coumadin 991 Yes
15 PAH group1 F 51 51 Lasix/coumadin 1199 Yes
16 PAH group1 F 48 73 Epoprostenol/Lasix 1800 Yes
17 PAH group1 F 51 41 Lasix 990 Yes
18 PAH group1 F 68 37 Lasix/coumadin/Norvasc 544 Yes
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(Gibco, Invitrogen, Burlington, ON, Canada) [20]. STAT3
was inhibited by a specific siRNA 20 nM for 48 h (Applied
Biosystems Canada) and KLF5 was inhibited by a specific
siRNA (30 nM for 48 h; Applied Biosystems Canada).
Control PASMC were exposed to either PDGF (30 nG/
mL); endothelin-1 (10 nM) or IL6 (20 ng/mL) (all from
EMB Canada). All experiments were realized with a
proper control siRNA scramble (siScr).
In vivo model rats
Male Sprague-Dawley rats were used in this study.
Monocrotaline (Sigma) was injected s.c. (60 mg/kg) to
induce PAH. Once PAH is established (2 weeks post
MCT injection), rats were treated by nebulization
directly in the lungs of KLF5 siRNA (20 μM). PA pres-
sure measurements have been realized by right heart
catheterization to evaluate PAH severity.
Quantitative RT-PCR
To measure KLF5 expression (using assay from Applied
Biosystem), total mRNA was extracted from PAH-
PASMC or control PASMC using trizol protocol. Quan-
tification of mRNA expression was performed as pre-
viously described [6].
Western Blot
Total protein extraction was realized on PASMC. KLF5
(Millipore; 1/500), PY705-STAT3 (Cell signaling; 1/
1000), STAT3 (Cell signaling; 1/1000), Survivin (Cell
signaling; 1/1000) and Cyclin B1 (Sigma Aldrich; 1/
1000) were quantified and normalized to the smooth
muscle actin (Santa cruz; 1/400) as previously described
[6]. Evaluation for PY705-STAT3/STAT3 and KLF5/
SM-actin were obtained from the same gel after strip-
ping (30 min at 50 degrees).
Confocal microscopy
TMRM, TUNEL, PCNA, Ki67 and AnnexinV were mea-
sured as previously described [6,21].
Statistical Analysis
V a l u e sa r ee x p r e s s e da sf o l dc h a n g eo rm e a n±S E M .
Unpaired Student’s t tests were used for comparisons
between two means. For comparisons between more
than two means we used one-way ANOVA followed by
aD u n n ’st e s t .AP value < 0.05 was considered statisti-
cally significant (and indicated with asterisks *).
Results
KLF5 is upregulated in human and rodent pulmonary
hypertension
To investigate the expression pattern of KLF5 in normal
and pulmonary hypertensive lungs, we examined KLF5
expression levels in 1) lung biopsies from 10 individuals
with non-familial PAH compared to biopsies from 8 indi-
viduals without pulmonary hypertension, 2) lungs from 5
rats with monocrotaline-induced pulmonary hypertension
compared to 10 control littermates (Figure 1A). We found
increased levels of KLF5 in human and rodent pulmonary
hypertensive lung tissues compared to normotensive lung
samples. Within the lungs, KLF5 upregulation in PAH is
confined to the distal PA (< 400 μm) (Figure 1A).
To test whether KLF5 upregulation is correlated with
disease progression, we studied humans and rats with
varying degrees of PAH. In both human subjects and
rodents, KLF5 levels in the lung correlated directly with
the severity of PAH, as measured by pulmonary vascular
resistance (PVR) in humans and mean PA pressure in
rodents (Figure 1B). Our results indicate that levels of
KLF5 correlate with the severity of PAH in humans and
experimental pulmonary hypertension.
To determine whether KLF5 expression in the pul-
monary circulation is restricted to PASMC we measured
KLF5 mRNA in human PASMC and PAEC. As shown
in Figure 1C, KLF5 is preferentially expressed in
PASMC. This finding was confirmed by co-localization
studies between KLF5 and smooth muscle actin (marker
of smooth muscle cell) or VE cadherin (marker of
endothelial cells) in human lung biopsies. As shown, a
greater co-localization was found between KLF5 and
smooth muscle actin than KLF5 and VE cadherin. This
finding confirms our qRT-PCR data and thus, that KLF5
is significantly more expressed in PASMC than PAEC
(Figure 1C). Hence, for the rest of the study we have
focused our research on PASMC. To determine whether
KLF5 is upregulated in PAH-PASMC we used human
cultured PASMC in the first to third passage. PAH-
PASMC were obtained from ≈1, 500 μm-diameter small
pulmonary arteries from 2 males with iPAH (31 and 48
years old) and 1 female with PAH group 1 (lupus; 54
years old) from lung explants [7]. All patients had right
catheterization that confirmed pulmonary hypertension
(mean PAP greater than 25 mmHg at rest). Age and sex
matched control PASMC (3 males 45; 21; 64 years old
and 2 females 17 and 35 years old)) were used. KLF5
upregulation between control and PAH was confirmed
by qRT-PCR and Western blot (WB) (Figure 1C). Note
that no significant differences in KLF5 expression was
found among the control patients and among the PAH
patients (not shown). Therefore for the rest of the study
all 5 control-PASMC and the 3 PAH-PASMC cell lines
were used for every cell-based experiment.
KLF5 is activated in PAH-PASMC through a STAT3
dependent mechanism
The Signal Transducers and Activators of Transcription
(STATs) family is composed of 7 isoforms (STAT1; 2; 3;
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one in cardiovascular diseases [22,23]. STATs are acti-
vated (i.e. phosphorylated) by either the Janus-activated
kinase (JAKs) or the Src family kinases in response to
cytokines (like IL-6, TNF...) [24], growth factors (like
PDGF...) [24] or agonists (like ET1, AngII...) [25], all of
which are implicated in PAH [26-28]. Interestingly, a
recent study in stem cells revealed a putative regulation
of KLF5 by STAT3 [29]. To demonstrate the implication
of STAT3 in the regulation of KLF5 expression in PAH,
KLF5 expression was measured in PAH-PASMC and
control PASMC in the presence or absence of STAT3
siRNA. Compared to siScr treated PAH-PASMC,
siSTAT3 treated PAH-PASMC had significantly reduced
KLF5 expression (Figure 2A). These findings suggest
that STAT3 activation accounts for KLF5 expression in
PAH-PASMC. To further confirm the implication of
STAT3/KLF5 axis in PAH, healthy-PASMC were treated
for 48 h with increasing doses of pro-PAH factors
[26-28] like ET1 (10 nM), PDGF (30 ng.mL
-1)a n dI L - 6
(20 ng.mL
-1). As expected, pro-PAH factors, increased
STAT3 activation (PY705-STAT3/STAT3 ratio) in ET1,
PDGF and IL-6 treated PASMC respectively (Figure 2B).
Interestingly, we found that in healthy-PASMC treated
with pro-PAH factors (ET1, PDGF or IL-6) the activa-
tion of STAT3 promotes KLF5 expression (Figure 2B).
KLF5 inhibition decreases PAH-PASMC proliferation and
resistance to apoptosis
To study the effect of KLF5 on PASMC proliferation
and apoptosis in vitro, cultured human PAH-PASMC
were either exposed to 10% FBS to promote prolifera-
tion or 0.1% FBS to promote apoptosis [6]. When com-
pared to control PASMC containing a low level of
KLF5, PAH-PASMC displayed higher cell proliferation
rate and resistance to induced apoptosis (Figure 3&4).
Figure 1 KLF5 expression is increased in PAH. A) KLF5 expression is measured by qRT-PCR in human lungs from patients with or without
PAH. KLF5 is increased in PAH-patient (n = 10) compared to control patients (n = 8). KLF5 expression is also increased in distal pulmonary
arteries (PA) of MCT-PAH-rats versus control rats (n = 10). B) KLF5 upregulation (measured by qRT-PCR) is correlated with PAH severity in human
lung evaluated by pulmonary vascular resistance (PVR). Similarly, KLF5 expression in rat lungs is correlated with mean PA pressure upregulation.
C) KLF5 upregulation (measured by (1) qRT-PCR or (2) Western blot) is confirmed in human pulmonary artery smooth muscle cell (PASMC)
isolated from healthy patients or PAH patients (3&4). All qRT-PCR results were normalized to 18S gene expression and protein expression was
measured by Western blot were normalized to SM-actin (*, P < 0.05; **, P < 0.01).
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KLF5 inhibition on PAH-PASMC proliferation. The
KLF5 inhibition using siRNA in PAH-PASMC decreases
proliferation to the level seen in control-PASMC (Figure
3A&3B). Note that siScr has no effect. The increased
proliferation seen in PAH-PASMC is associated with a
KLF-5-dependent up-regulation of cyclin B1, confirming
previous findings in systemic vessels [30] and cancer
[31] (Figure 3C). Moreover, we confirmed that siKLF5
decreased significantly KLF5 (Figure 3D).
Resistance to apoptosis observed in PAH-PASMC has
been linked to mitochondrial membrane potential
(ΔΨm) hyperpolarization, which would block the release
of pro-apoptotic mediators like cytochrome c [6,20,21].
Using tetramethylrhodamine methyl ester (TMRM), we
measured whether KLF5 inhibition can affect
mitochondrial hyperpolarization. We observed that
KLF5 inhibition in PAH-PASMC depolarizes ΔΨm to a
level similar to that observed in control-PASMC (Figure
4A). Finally, mitochondrial depolarization induced by
KLF5 inhibition in PAH-PASMC increases serum star-
vation-induced apoptosis (TUNEL, annexin V) (Figure
4B&4C). We previously published that ΔΨm hyperpolari-
zation was associated to the upregulation of the onco-
protein survivin and that survivin inhibition in PAH-
PASMC reverses mitochondrial hyperpolarization, pro-
moting apoptosis. Nonetheless, the mechanism account-
ing for survivin expression in PAH-PASMC remains
elusive. Recently, in cancer, KLF5 has been shown to
promote survivin expression. To determine whether the
survivin upregulation in PAH-PASMC is KLF5 depen-
dent, survivin expression was measured in PAH-PASMC
Figure 2 STAT3 activation increases KLF5 expression. A) STAT3 inhibition by siRNA decreases KLF5 RNA expression measured by qRT-PCR in
human PAH-PASMC and protein expressions were measured by Western blot. B) STAT3 activation (i.e. PY705-STAT3/STAT3 ratio) and KLF5
expression were measured in control cells with or without stimulation (ET-1, PDGF, IL-6), by Western blot. Our results show that ET1, PDGF and
IL6 stimulations induce STAT3 activation and upregulation of KLF5 expression. qRT-PCR results were normalized to 18S gene expression and
protein expression measured by Western blot were normalized to SM-actin (*, P < 0.05; **, P < 0.01).
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KLF5 inhibition decreases survivin expression (Figure
4D) and thus provides a putative mechanism accounting
for the KLF5-dependent ΔΨm hyperpolarization seen in
PAH-PASMC.
KLF5 inhibition in vivo improves PAH
To confirm the STAT3-dependent regulation of KLF5,
in vivo rats were injected with monocrotaline for 4
weeks. Once PAH established (increased PA pressure
and increased right ventricle wall hypertrophy (RVH)),
rats were nebulized with either siSTAT3 or siScr for 2
weeks. Effects on PAH (mean PA pressure; RVH) were
measured by right catheterization and Fulton index.
KLF5 expression was measured immunofluorescence in
distal PA (Figure 5B). As shown, siSTAT3 decreases
KLF5 expression and PAH in distal PA, confirming our
in vitro findings (Figure 2A). Note that the efficiency of
our therapeutic intervention was confirmed i.e. siSTAT3
significantly decreases STAT3 in distal PA. Among all
the rats treated with siSTAT3, the rats showing the
greater KLF5 downregulation had the lower mean PA
pressure, suggesting that KLF5 is implicated in the etiol-
ogy of PAH. To determine whether KLF5 has direct
therapeutic potential for PAH, monocrotaline rats (with
established PAH 2 weeks post injection) were nebulized
Figure 3 KLF5 inhibition decreases proliferation. A&B) PASMC cell proliferation was evaluated by PCNA and Ki67 immunostaining (nuclear
translocation). PAH PASMC are significantly more proliferative than control PASMC and KLF5 inhibition (siRNA) decreases PAH-PASMC
proliferation compared to siScr. C) Cyclin B1 (a proliferation biomarker) is increased in PAH-PASMC and KLF5 inhibition decreases significantly
cyclin B1 expression. D) KLF5 inhibition in PAH-PASMC has been evaluated by qRT-PCR and Western blot. KLF5 inhibition, in PAH-PASMC using
siRNA, decreases significantly KLF5 expression compared to the appropriate control: PAH-PASMC with siRNA Scramble (siScr). qRT-PCR were
normalized to 18S gene and Western blot were normalized to SM-Actin (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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intervention was confirmed in distal PA where KLF5
expression is significantly decreased (Figure 5B). As
shown, KLF5 inhibition improves PAH by reducing
RVH and mean PA pressure (Figure 5A).
Discussion
Here we show that KLF5 is etiologically associated with
the development of PAH, and believe that we have
opened a new avenue for PAH treatment. KLF5 is
expressed in established human and experimental PAH.
Its expression is dependent of the activation of STAT3.
We provided evidences that KLF5 inhibition improves
PAH by 1) the inhibition of cyclin B1 and PASMC pro-
liferation and 2) the depolarization of PASMC mito-
chondria by inhibiting survivin activation thus
increasing apoptosis. These findings not only confirm
what has been shown in cancer [16,31,32] and systemic
vascular smooth muscle cells [33,34] in which KLF5
inhibition decreases proliferation through cell cycle pro-
tein inhibition like cyclin B1 and p21 upregulation, but
also provide a better demonstration of the involvement
of KLF5 in mitochondrial-dependent apoptosis. In fact,
we provide for the first time evidences that KLF5 is
implicated in mitochondrial membrane potential regula-
tion through the upregulation of the oncoprotein survi-
vin. We have previously extensively demonstrated the
mechanism of mitochondrial membrane potential regu-
lation by survivin in PAH-PASMC [7], but had not elu-
cidated the mechanism accounting for its upregulation.
Our new findings propose that KLF5 activation might
explain such upregulation. In fact, we showed that KLF5
inhibition decreases survivin expression in PAH-
PASMC. This is associated with a significant mitochon-
drial depolarization. This finding could be of great ther-
apeutic interest as it provides a new insight on the
regulation of survivin that is implicated in many cancer
and cardiovascular diseases [35-39]. Thus, our findings
might not be limited to PAH but can be extend to
many other diseases including cancer. To this end, a
recent report has demonstrated a link between KLF5
and survivin in cancer [40].
Previous studies reported that KLF5 is implicated in
embryonic stem cells and VSMC differentiation contri-
buting to vascular lesions [34,41]. This aspect might be
implicated in the vascular lesions seen in PAH patients.
Indeed, vascular lesions such as remodeled arteries and
plexiform lesions are seen in patients with PAH. Studies
have demonstrated the implications of abnormal stem
cells in this phenomenon [42]. KLF5 implication in such
processes cannot be ruled out.
The activation of KLF5 axis that we described likely
has a multifactorial etiology in PAH. However, KLF5
might be a critical integrator of multiple signaling
Figure 4 KLF5 inhibition promotes apoptosis. A) Mitochondrial membrane potential was measured by TMRM in confocal microscopy. PAH-
PASMC are more hyperpolarized than control (more red) and KLF5 inhibition (siRNA) depolarized PAH-PASMC. B&C) Apoptosis was also
evaluated by TUNEL and Annexin V staining in PASMC. PAH-PASMC are more resistant to starvation induced apoptosis (0, 1%FBS) than control
PASMC. KLF5 inhibition in PAH-PASMC promotes apoptosis. D) Survivin expression (measured by Western blot) is increased in PAH-PASMC
compared to control cells and KLF5 inhibition (siRNA) decreased survivin expression. Western blot were normalized to SM-actin (*, P < 0.05; ***,
P < 0.001).
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eral and important features of PAH. In vivo, endothelial
dysfunction is recognized as one of the earliest abnorm-
alities in PAH, resulting in a well-recognized imbalance
of endothelium-derived vasoactive factors; with
increased vasoconstrictors (like endothelin [28], throm-
boxane [1] and decreased vasodilators (like NO or pros-
tacyclin [1]). Recently, KLF5 has been shown to be
implicated in endothelial dysfunction [43]. In addition,
increased circulating growth factor (like PDGF) [27] and
cytokines (like IL-6, MCP-1...) [26] have been reported
in PAH, and there is numerous evidences demonstrating
the implication of KLF5 in both growth factor and cyto-
kines production regulation [18,43-45].
Finally, we have previously extensively demonstrated
the implication of HIF-1 in triggering mitochondrial and
[Ca
2+]i dysfunction sustaining the pro-proliferative and
anti-apoptotic phenotype seen in PAH-PASMC [5,46].
Interestingly, Mori et al. have shown that cooperation
between HIF-1 and KLF5 might exist [47]. Indeed, KLF5
inhibition decreases the expression of several HIF-1-
regulated genes in cancer cells, while HIF-1 inhibition
affects KLF5 expression [47]. These findings in cancer
cells implied that interaction between HIF-1/KLF5 in
PAH-PASMC might exist. Thus, all these reports sug-
gest that KLF5 might play a critical role in the etiology
of PAH. Surprisingly no studies have been performed
on the topic.
The mechanisms accounting for KLF5 upregulation in
PAH remain to be established. Recently, a study from
Cheng et al [48] has suggested the implication of the
microRNA 145 (miR-145). In their study, they provided
evidences that the downregulation of miR-145 promotes
vascular neointimal lesion formation through the
Figure 5 In vivo, KLF5 inhibition reverses PAH development. A) Mean PA pressure was measured on closed chest rats by right
catheterization. The mean PA pressure is increased significantly in PAH, whereas KLF5 and STAT3 inhibition (siRNA) decrease the pulmonary
pressure. The right ventricular hypertrophy, evaluated by Fulton index measurement, is reversed with KLF5 and STAT3 inhibition. Pulmonary
Vascular Resistances (PVR) are increased in PAH rats and KLF5 or STAT3 inhibition decreased them. B) KLF5 activation has been evaluated in
distal pulmonary arteries from rats by immunofluorescence. Nuclear colocalization of KLF5 is increased in PAH-PASMC from distal PA compared
to healthy PA and KLF5 and STAT3 inhibition decrease KLF5 translocation. Proliferation and apoptosis have been evaluated by
immunofluorescence (respectively by Ki67 and TUNEL). Proliferation increases in PAH-PA compared to control PA was decreased after treatment
with siKLF5 or siSTAT3. Apoptosis resistance of the PA-PAH is reversed after KLF5 and STAT3 inhibition (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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miR-145 in PAH, has not been demonstrated [49]. We
believe that one of the initial events in PAH, regardless of
the specific cause, is the activation of the miR-204/STAT3
axis [50], which increases KLF5 expression (Figure 2), sup-
porting the notion that KLF5 induction is an early event
during PAH. Thus, KLF5 upregulation can be caused by
many diverse conditions that lead to PAH in addition to
hypoxia, including growth factors, vasoactive molecules
[50,51], or viral infection of PASMC [52]. The fact that
STAT3 activation may occur only in pulmonary, not sys-
temic, vasculature [50] explains the selective induction of
KLF5 in the pulmonary circulation. This finding strength-
ens the argument that KLF5 therapeutic targeting may
achieve relative selectivity for the pulmonary circulation in
PAH. Although many more experiments are needed in
order to determine whether this regulation is direct or
indirect, this finding is of great interest. In fact, STAT3
has been associated with many feature of PAH including
BMPR2 downregulation (hallmark of PAH) [53]. Involve-
ment of KLF5 in the STAT3-mediated effects in PAH will
certainly open new avenues of investigation. Finally, we
showed that both indirect (through STAT3 inhibition) and
direct KLF5 inhibition (nebulized siRNA) improve PAH.
Nonetheless, we should note that STAT3 inhibition
showed a greater efficiency than siKLF5. This is not sur-
prising as STAT3 has been implicated in many features
characterizing PAH, including miRNA such as miR-204,
Pim1; NFAT; BMPR2 [6,50,51,53]
Conclusion
Although our findings will need to be repeated in
greater amount of patients and at different stages of
PAH to have a better understanding of the role of KLF5
in PAH, nonetheless our study suggests for the first
time the implication of KLF5 in the etiology of human
PAH. Moreover we provide evidences that its activation
might account for many feature seen in PAH, including
PASMC proliferation, mitochondrial hyperpolarization,
survivin expression and resistance to apoptosis. Because,
pulmonary arterial hypertension is a rapidly lethal dis-
ease for which treatments are limited, we believe that
our findings will open the door to new avenues of inves-
tigation and potentially future therapies for PAH.
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